SCHEMBL4039628

SCHEMBL4039628

O=C1c2ccccc2C(=O)N1C1CC2CCC(C1)N2Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.49
CA9 Q16790 1/20 0.49
APAF1 O14727 2/20 0.48
ALDH1A1 P00352 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
BCHE P06276 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
MAPT P10636 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
ALOX12 P18054 1/20 0.48
ACHE P22303 1/20 0.48
CES1 P23141 1/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
DRD2 P14416 1/20 0.47
DRD4 P21917 1/20 0.47
DRD3 P35462 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7540180 0.94 CA12 (0.45) CA12CA9APAF1ALDH1A1TP53
SCHEMBL7542931 0.94 CA12 (0.45) CA12CA9APAF1ALDH1A1TP53
SCHEMBL4037015 0.76 DRD2 (0.55) ALDH1A1DRD2DRD4DRD3ARG1
SCHEMBL4037021 0.76 DRD2 (0.55) ALDH1A1DRD2DRD4DRD3ARG1
SCHEMBL4036159 0.76 DRD2 (0.55) ALDH1A1DRD2DRD4DRD3ARG1
SCHEMBL4036161 0.76 DRD2 (0.55) ALDH1A1DRD2DRD4DRD3ARG1
SCHEMBL4034860 0.76 KMT2A (0.51) APAF1ALDH1A1TP53CYP1A2BCHE
SCHEMBL4039195 0.76 DRD2 (0.55) ALDH1A1DRD2DRD4DRD3ARG1
SCHEMBL11094859 0.74 ARG1 (0.54) ALDH1A1DRD2DRD4DRD3ARG1
SCHEMBL11094861 0.74 ARG1 (0.54) ALDH1A1DRD2DRD4DRD3ARG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212299-B1 SUBSTITUTED PIPERIDINE COMPOUNDS USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA UK LTD (GB) 2009-04-08 EP disclosed
US-20050250792-A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity MERRILL LYNCH CAPITAL, A DIVISION OF MERRILL LYNCH BUSINESS FINANCIAL SERVICES, INC. AS ADMINISTRATIVE AGENT 2005-11-10 US disclosed
US-6903085-B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity ASTRAZENECA, AB (CH) 2005-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250792-A1 Substituted piperidine compounds useful as modulators of chemokine receptor activity CXCR4, CXCR1, CXCR3 CA12 4823/4885CA9 4552/4885APAF1 2016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.